Core Viewpoint - Enphase Energy, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its financial and operational prospects, particularly related to inventory management and the impact of the expiration of the Residential Clean Energy Credit [1] Summary by Relevant Sections Class Action Lawsuit Details - The class action lawsuit is titled Tripathi v. Enphase Energy, Inc., and covers the period from April 22, 2025, to October 28, 2025 [1] - Investors who suffered substantial losses during this period have until April 20, 2026, to seek appointment as lead plaintiff [1] Allegations Against Enphase Energy - The lawsuit alleges that Enphase Energy overstated its ability to manage channel inventory and mitigate the effects of the termination of the Residential Clean Energy Credit [1] - It is claimed that these misrepresentations led to an overstatement of the company's financial and operational prospects [1] - Following the disclosure of financial results on October 28, 2025, Enphase Energy's stock price fell by more than 15% due to expected lower battery storage shipments and revenue impacts from the expiration of the 25D Credit [1] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Enphase Energy securities during the class period to seek lead plaintiff status [1] - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [1] - Participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery [1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years [1]

Core Viewpoint - The Corcept class action lawsuit alleges that Corcept Therapeutics and its executives misrepresented the status of their New Drug Application (NDA) for relacorilant, leading to significant financial losses for investors when the FDA issued a Complete Response Letter (CRL) indicating concerns about the clinical evidence supporting the NDA [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers of Corcept common stock from October 31, 2024, to December 30, 2025 [1]. - The lawsuit is titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated and is filed in the Northern District of California [1]. - The allegations include that Corcept misled investors about the FDA's review process and the adequacy of clinical evidence for relacorilant [3][4]. Group 2: FDA Concerns - The FDA had raised concerns about the clinical evidence supporting the NDA for relacorilant, indicating a material risk of non-approval [3]. - On December 31, 2025, Corcept disclosed that the FDA issued a CRL, stating it could not make a favorable benefit-risk assessment without additional evidence [4]. - A redacted copy of the CRL published on January 30, 2026, detailed the FDA's concerns regarding the sufficiency of the clinical studies submitted [5]. Group 3: Legal Process - Investors who suffered losses during the class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [6]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE:KD) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your Kyndryl investments, you have until April 13, 2026 to request lead plaintiff appointment. Court ...

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Cogent Communications Holdings, Inc., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1]. Company Overview - Cogent Communications provides high-speed internet access, private network, and data center colocation space services [3]. Financial Performance - On November 6, 2025, Cogent Communications reported a year-over-year service revenue decrease of nearly 6% for the third quarter of 2025 [3]. - The company announced a significant dividend cut of 98%, reducing it from $1.015 per share in the prior quarter to $0.02 per share [3]. - Following the financial results announcement, Cogent Communications' share price fell nearly 35% [3].

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL). If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-grail-inc-investigation-gral.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 8 ...

Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to seek lead plaintiff status: April 6, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s drug, setrusumabInvestor action: Contact Kessler Topaz Meltzer & Check, LLP (www. ...

Fermi (FRMI) Faces Securities Class Action Over Alleged $150M Anchor Tenant Exit - Hagens Berman [Accessibility Statement] Skip NavigationPartner Reed Kathrein Scrutinizing Claims of High Conviction Against Revealed Construction Funding Collapse and 33% Stock CrashSAN FRANCISCO, Feb. 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing an updated notice to investors in Fermi Inc. (NASDAQ: FRMI) regarding the March 6, 2026, lead plaintiff deadline in a pending securities cla ...

BRBR Alert: BellRing Brands (BRBR) Facing Securities Class Action Over Alleged Artificial Growth and $2.9 Billion Value Wipeout - Hagens Berman [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing an updated notice to investors in BellRing Brands, Inc. (NYSE: BRBR) regarding the March 23, 2026, lead plaintiff deadline accusing BellRing and certain of BellRing's top executives of securities fraud.[CLICK HERE TO SUB ...

Core Viewpoint - Hagens Berman is investigating Varonis Systems, Inc. (NASDAQ: VRNS) over allegations of failing to disclose significant issues related to its transition to a Software-as-a-Service (SaaS) model, which has led to a substantial decline in revenue and stock value [1]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Varonis executives concealed renewal softness in its Federal vertical and legacy on-premises business while promoting a successful transition to SaaS [1]. - Following a disclosure on October 28, 2025, Varonis reported a 63.9% year-over-year decline in term license revenue and a reduced Annual Recurring Revenue (ARR) outlook, resulting in a 48% drop in stock price, equating to a loss of approximately $3.8 billion in market value [1]. - The investigation focuses on whether Varonis violated federal securities laws by failing to disclose the significant decline in renewals and the challenges in converting existing customers to the SaaS model [1]. Group 2: Financial Impact and Stock Performance - On the news of the revenue decline, Varonis shares plummeted from $63.00 to $32.34 in a single day, representing a nearly 50% loss in shareholder value [1]. - The company significantly reduced its Q4 revenue and full-year ARR guidance following the Q3 performance miss, indicating a serious impact on its financial outlook [1]. - The lawsuit alleges that Varonis misrepresented its ability to convert on-premises customers to SaaS, claiming strong retention and renewal rates, which were contradicted by the actual performance [1]. Group 3: Next Steps for Investors - Hagens Berman is advising investors who purchased VRNS shares during the class period from February 4, 2025, to October 28, 2025, and experienced substantial losses to contact the firm [1]. - The lead plaintiff deadline for the pending lawsuit is set for March 9, 2026, urging affected investors to take action [1].

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against NuScale Power Corporation (NYSE: SMR) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired NuScale securities between May 13, 2025 and November 10, 2025, both ...